氢吗啡酮联合右美托咪定治疗临终期病人重度癌痛的临床疗效观察

The clinical observation of hydromorphone combined with dexmedetomidine in the treatment of severe cancer pain in terminal patients

目的:探讨氢吗啡酮联合右美托咪定用于临终期病人重度癌痛的效果和安全性。方法:采用回顾性研究的方法,选取2020年1月至2022年11月沧州市人民医院疼痛(安宁疗护)科癌症临终期病人53例,按有无接受右美托咪定联合治疗分为对照组30例,应用单纯应用氢吗啡酮镇痛治疗;试验组23例,应用氢吗啡酮联合右美托咪定镇痛治疗。比较两组治疗后7天内镇痛效果、焦虑程度及治疗后15天内不良反应发生率。结果:两组病人镇痛治疗后疼痛明显缓解(P<0.05),试验组焦虑水平较对照组下降明显(P<0.05),且不良反应发生率低于对照组。结论:氢吗啡酮联合右美托咪定可以缓解临终期病人重度癌痛,降低焦虑水平,且不会增加不良反应的发生,值得临床推广。

Objective:To explore the efficacy and safety of hydromorphone combined with dexmedetomidine(Dex)in the treatment of severe cancer pain in terminal patients.Methods:A retrospective study was conducted.From January 2020 to November 2022,53 patients with Cancer in The Department of Pain Management(Palliative Care)of Cangzhou People's Hospital were selected,and 30 patients in the control group were treated with hydromorphone only,23 patients in the experimental group were treated with hydromorphone combined with Dex for analgesia.The analgesic effect,anxiety degree and the incidence of adverse reactions within 15 days after treatment were compared between the two groups.Results:After analgesic treatment,the pain in the two groups was obviously relieved(P<0.05),the anxiety level in the experimental group was significantly lower than that in the control group(P<0.05),and the incidence of adverse reactions in the experimental group was lower than that in the control group.Conclusion:Hydromorphone combined with dexmedetomidine can relieve the severe cancer pain of terminal patients,reduce the anxiety level,and will not increase the occurrence of adverse reactions,which is worthy of clinical promotion.